NCT01209130View on ClinicalTrials.gov

A Study of the Safety and Pharmacokinetics of Escalating Doses of DCDT2980S in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia And DCDT2980S in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non Hodgkin's Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

91

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions
Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia
Interventions
DRUG

DCDT2980S

Intravenous repeating dose

DRUG

rituximab

Intravenous repeating dose

Trial Locations (9)

20057

Washington D.C.

48109

Ann Arbor

53705

Madison

80218

Denver

97239

Portland

94305-5821

Stanford

02114

Boston

02215

Boston

07601

Hackensack

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY